Multiple Myeloma

GSK Blenrep wins FDA approval in relapsed multiple myeloma

GSK’s Blenrep has returned to the U.S. market after the FDA approved it in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma. The catalyst matters for BD teams and investors because it reverses a prior withdrawal and resets the drug’s U.S. label and commercial outlook.

Tempest Therapeutics TPST-2003 CAR-T Shows Promise for Multiple Myeloma at ISCT 2026

Tempest Therapeutics presents positive TPST-2003 dual-targeting CAR-T data for relapsed/refractory multiple myeloma patients at ISCT 2026 meeting.

Pfizer's ELREXFIO Shows Significant Progression-Free Survival Improvement in Multiple Myeloma Phase 3 Trial

Pfizer's ELREXFIO meets primary endpoint in MagnetisMM-5 Phase 3 trial, showing statistically significant progression-free survival improvement for relapsed multiple myeloma patients.

FDA Extends Sanofi Sarclisa Subcutaneous Review by Three Months for Multiple Myeloma Treatment

FDA extends Sarclisa subcutaneous review by 3 months. Sanofi's multiple myeloma treatment seeks approval across all current IV indications.

FDA Approves Talvey (talquetamab) for Relapsed Multiple Myeloma

The FDA has granted approval for Talvey (talquetamab), a groundbreaking treatment option for patients with relapsed multiple myeloma, enhancing therapeutic choices.